CIDRAP newsletters options
High-flow oxygen didn't significantly lower death rates beyond those of standard oxygen therapy in COVID-19 patients with respiratory failure, according to a multicenter randomized clinical trial published yesterday in JAMA.
The Americas house 13% of the world's people, but the region has seen 37% of global cases and 45% of deaths.
Data suggest "boosters continued to provide protection against severe illness despite viral evolution."
A report published yesterday in Clinical Infectious Diseases describes a new SARS-CoV-2 mutation that confers resistance to the COVID-19 antiviral drug remdesivir in two persistently infected kidney transplant recipients treated with immunosuppressive drugs.
Three doses of an mRNA vaccine were tied to a 59% lower odds of hospital care than 2 doses.
Illnesses have been reported in 2 more locations.
A new study based on COVID-19 patients in France shows high reinfection rates among people with different Omicron subvariants, including BA.1, BA.2, and BA.5. The study is published as a research letter in Emerging Infectious Diseases.
According to a new non-peer reviewed study out of Israel, the Jynneos vaccine is 79% effective against monkeypox infection.
The study was based on patients eligible for monkeypox vaccine seen in the Clalit Health Services system between Jul 31 and Sep 12, 2022. Of 1,970 subjects eligible for the study, 873 (44%) were vaccinated with Jynneos and completed at least 25 days of follow-up.
"We may see a substantial increase in this disease in the coming months to years."
US experts are closely watching the developments to see how the next months might unfold.
Swiss biopharmaceutical company Ferring Pharmaceuticals announced yesterday that the Food and Drug Administration's (FDA's) Vaccine and Related Biologic Products Advisory Committee (VRBPAC) voted in favor of the company's investigational fecal microbiota transplant (FMT)-based therapy.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
The risk of a range of neurologic conditions rose significantly in the year after COVID-19 infection among a group of US veterans—regardless of whether they had required hospitalization, according to a study published yesterday in Nature Medicine.
Steady drops in new cases continue in North America and Europe, resulting in a 22% overall decline.
One study reveals signs of autoimmune disease in 41% of blood samples 1 year after recovery.
MRI reveals lung damage in children who either had COVID-19 up to a year earlier or have long COVID.
A studye suggests human, animal, and environmental exposures may all play a role.
The WHO says the outbreak location and its mobile population pose a risk of further spread.
A study in The Lancet Infectious Diseases demonstrates that previous Omicron BA.1 infection was the most protective factor against BA.2 infection (associated with a risk reduction of 72%) and gave greater protection than primary infection with pre-Omicron SARS-CoV-2 (38%) or three doses of an mRNA vaccine in people with no previous infection (46%).
Biopharmaceutical company Spero Therapeutics announced today that it has entered into a licensing agreement with GSK for the antibiotic tebipenem pivoxil hydrobromide (HBr).
